Lantern Pharma (NASDAQ: LTRN), an AI-native precision oncology company, announced that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 clinical trial evaluating its lead drug candidate LP-184 (zirdafulven) in patients with advanced or metastatic bladder cancer. The biomarker-guided study, to be conducted at Rigshospitalet in Copenhagen, Denmark, will enroll up to 39 patients and prospectively select participants based on PTGR1 overexpression and DNA-damage-repair deficiency. According to the company, the trial will evaluate LP-184 in patients who have progressed on or are ineligible for current standard-of-care therapies, while further advancing its AI-driven precision oncology strategy through its proprietary RADR platform.
Bladder cancer is a significant global health burden, with limited treatment options for patients who relapse after initial therapy. The clearance of this trial in Europe marks an important step in addressing an unmet medical need. By using biomarkers to select patients most likely to respond, Lantern aims to improve outcomes and reduce unnecessary exposure to ineffective treatments. This approach could set a precedent for how bladder cancer trials are designed in the future, potentially leading to more personalized and effective therapies.
The implications for patients are substantial. For those with advanced or metastatic bladder cancer who have exhausted standard options, LP-184 may offer a new therapeutic avenue. The trial's biomarker-driven design means that only patients with specific molecular characteristics will be enrolled, increasing the likelihood of benefit. For the industry, this trial underscores the growing role of artificial intelligence and machine learning in drug development. Lantern's RADR platform, which analyzes genomic data to predict drug sensitivity, is central to identifying the biomarker for PTGR1. Successful results could validate the platform's utility and encourage broader adoption of AI-driven approaches in oncology.
Lantern Pharma's clinical pipeline also includes LP-284, targeting TC-NER in hematologic and solid tumors, and LP-300, a cisplatin analog being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary. The company's withZeta.ai platform, a multi-agentic AI co-scientist, is now commercially available as a subscription-based research platform, representing a new revenue stream.
For more information on the press release, visit https://ibn.fm/6ku4F. For the latest news on Lantern Pharma, see the company's newsroom at https://ibn.fm/LTRN.
